Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791531 | 0.86 | NAMPT (0.48) | NAMPTEGLN1SLC40A1ARENPP2 | |
| SCHEMBL12184925 | 0.86 | NAMPT (0.48) | NAMPTEGLN1SLC40A1ARENPP2 | |
| SCHEMBL26968221 | 0.81 | CHEK1 (0.46) | NAMPTEGLN1CHEK1SLC40A1AR | |
| SCHEMBL2586677 | 0.79 | L3MBTL1 (0.52) | NAMPTEGLN1AR | |
| SCHEMBL29812320 | 0.79 | SMN1; SMN2 (0.57) | CYP2D6CYP2C9 | |
| SCHEMBL23021014 | 0.78 | GABRP (0.56) | NAMPTCHEK1ARPARP14TSHR | |
| Hydrochloric Acid SCHEMBL6969707 | 0.78 | L3MBTL1 (0.51) | NAMPTEGLN1ARADORA2AADORA2B | |
| SCHEMBL6348729 | 0.78 | LOXL2 (0.52) | NAMPTEGLN1CHEK1ARENPP2 | |
| SCHEMBL26469110 | 0.77 | CHEK1 (0.41) | NAMPTEGLN1CHEK1SLC40A1AR | |
| SCHEMBL18695334 | 0.76 | MYC (0.42) | PARP14ENPP2CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7125883-B1 | Integrin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2006-10-24 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | NAMPT 773/4885EGLN1 4114/4885CHEK1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.